Business Context and Reporting Period
This Form 8-K was filed by NextCure, Inc. on August 8, 2019. The filing serves as a Regulation FD disclosure providing an update on the Phase 1 portion of a Phase 1/2 clinical trial for the company's lead candidate, NC318, in patients with advanced or metastatic solid tumors.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on clinical trial progress. The text notes that the company has a history of significant losses and no products approved for commercial sale.
Material Changes and Clinical Progress
As of March 31, 2019, 21 patients had been dosed in the trial with no dose-limiting toxicities observed. Key efficacy observations include:
- Partial Response: One lung cancer patient in the 8mg cohort showed a 40% reduction in target lesions at 8 weeks, 80% at 16 weeks, and undetectable lesions at 24 weeks.
- Additional Response: A different patient in the 80mg cohort, who had not responded to prior salvage therapy, showed a confirmed 20% tumor reduction after 16 weeks.
- Overall Status: As of March 31, 2019, 6 patients had stable disease and 6 had disease progression.
- Safety: The drug was well tolerated, with some patients experiencing Grade 1/2 immune-mediated adverse events such as rash and diarrhea.
Guidance, Outlook, and Risks
Outlook: Enrollment in the Phase 1 portion remains on schedule. The company expects to present topline data from the Phase 1 portion in the fourth quarter of 2019. Completion of the Phase 2 portion is expected in the fourth quarter of 2020. No further updates are planned prior to the fourth quarter of 2019.
Risks and Contingencies: The filing highlights substantial risks, including the company's limited operating history, lack of approved products, history of significant losses, and the need to obtain additional financing. It also notes that preliminary results are not predictive of future results and that the unproven approach to the FIND-IO platform carries development risks.
Investor Verification Checklist
- Verify the company's current cash runway and need for additional financing as referenced in the risk factors.
- Confirm the timeline for the fourth quarter 2019 topline data presentation.
- Review the Form 10-Q filed on June 10, 2019, for detailed financial position and liquidity metrics not included in this 8-K.
- Monitor the transition from Phase 1 to Phase 2 enrollment and the specific tumor types selected for the Phase 2 portion.